Antiviral prophylaxis for hepatitis B virus reactivation in T-cell lymphoma patients with resolved hepatitis B virus infection.

This retrospective study evaluated the impact of anti-HBV prophylaxis on HBV reactivation in T-cell lymphoma (TCL) patients with resolved HBV infection who were undergoing anti-lymphoma therapy.

Among 174 propensity score-matched patients:

• 0% of patients receiving prophylactic anti-HBV treatment experienced HBV reactivation.
• 5.7% of patients in the non-prophylaxis group experienced HBV reactivation, with a significantly higher cumulative reactivation risk.

Reactivation in the non-prophylaxis group caused treatment delays or discontinuations.

These results suggest that anti-HBV prophylaxis may effectively reduce HBV reactivation and help maintain uninterrupted lymphoma treatment in this patient population.